- Home
- LX vs LRMR Comparison
LX vs LRMR Comparison
Compare LX & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LX | LRMR |
|---|---|---|
| Founded | 2013 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.4M | 455.8M |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LX | LRMR |
|---|---|---|
| Price | $2.27 | $4.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $3.50 | ★ $16.43 |
| AVG Volume (30 Days) | 1.2M | ★ 6.8M |
| Earning Date | 03-19-2026 | 03-19-2026 |
| Dividend Yield | ★ 16.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,368.04 |
| P/E Ratio | $2.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.26 | $1.61 |
| 52 Week High | $11.64 | $6.42 |
Technical Indicators
Market Signals| Indicator | LX | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 25.80 | 54.32 |
| Support Level | N/A | $3.09 |
| Resistance Level | $2.73 | $5.37 |
| Average True Range (ATR) | 0.11 | 0.40 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 2.11 | 33.89 |
Price Performance
Historical ComparisonAbout LX LexinFintech Holdings Ltd.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.